Louis Picker | HIV cure | Innovative Research Award

Innovative Research Award

Louis Picker
Oregon Health & Science University
Researcher Information
Affiliation Oregon Health & Science University
Country United States
Scopus ID 7005304033
Documents 257
Citations 37,921
h-index 90
Subject Area HIV cure
Event International Research Awards on Infectious Diseases

The Innovative Research Award recognizes scholarly contributions associated with significant and sustained research activity. This article presents an academic profile of Louis Picker of Oregon Health & Science University, with particular reference to research relevant to HIV cure strategies, scientific publications, citation performance, and the suitability of his research record for recognition through the International Research Awards on Infectious Diseases.[1]

Abstract

Louis Picker is a researcher at Oregon Health & Science University whose scholarly record is associated with major investigations in immunology, virology, vaccine science, and HIV cure research. His Scopus profile reports 257 documents, 37,921 citations, and an h-index of 90, indicating substantial publication visibility and long-term citation influence. This profile evaluates his research background, contributions, publication activity, research impact, and relevance to the Innovative Research Award within the International Research Awards on Infectious Diseases, using publicly presented academic metrics and representative scientific literature.[1]

Keywords

Innovative Research Award, Louis Picker, HIV cure, HIV immunology, infectious diseases, vaccine research, persistent viral infection, Scopus, research impact, Oregon Health & Science University.[1]

Introduction

Research on HIV continues to require advances in viral persistence, host immunity, prevention, therapeutic intervention, and cure-oriented strategies. Academic recognition in this field commonly considers sustained scientific productivity, influence on subsequent research, methodological development, and relevance to unresolved infectious disease challenges. Louis Picker’s publication record provides a basis for examining these criteria within an academic recognition context.[2]

Research Profile

Louis Picker is affiliated with Oregon Health & Science University in the United States. His research profile includes work relevant to viral immunology, T-cell biology, vaccine approaches, and persistent infections. The subject area identified for this article is HIV cure, reflecting research questions concerning durable immune responses and strategies directed toward controlling or eliminating persistent infection.[1]

Research Contributions

Research associated with Picker has examined unconventional immune mechanisms and the potential of cytomegalovirus-based vaccine vectors to generate distinctive cellular immune responses. Published studies have also investigated vaccine-mediated control of simian immunodeficiency virus, providing experimental evidence relevant to broader discussions of immune-based approaches to persistent viral infection and HIV cure research.[2]

Publications

The Scopus author record associated with Scopus ID 7005304033 reports 257 documents. This publication activity spans a substantial scholarly record and provides measurable evidence of continued research dissemination. Representative publications address vaccine vectors, cellular immunity, and persistent viral infection, including studies that have contributed to scientific discussion concerning immune-mediated control of lentiviral disease.[1][2]

Research Impact

The profile reports 37,921 citations and an h-index of 90, metrics that indicate broad citation activity across the research record. Citation indicators do not independently measure scientific quality or practical impact, but they provide one quantitative perspective on how frequently published work has been referenced within subsequent scholarship. These indicators support assessment alongside research relevance and documented contributions.[1]

Award Suitability

Based on the reported publication volume, citation record, h-index, institutional affiliation, and research relevance to HIV and infectious diseases, the profile presents characteristics consistent with consideration for the Innovative Research Award. The final suitability determination would depend on the award’s formal eligibility criteria, nomination materials, supporting evidence, and comparative evaluation procedures established by the event organizers.[3]

Conclusion

Louis Picker’s academic profile reflects sustained publication activity and substantial citation visibility in areas relevant to infectious disease and HIV research. His documented work on immunological mechanisms and vaccine-based approaches provides a scholarly basis for consideration within research recognition programs. The Innovative Research Award profile should be interpreted alongside formal verification and event-specific evaluation criteria.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Louis Picker, Author ID 7005304033. Scopus.
    https://www.scopus.com/pages/authors/7005304033
  2. Grossman, Z., Meier-Schellersheim, M., Paul, W. E., & Picker, L. J. (n.d.). Pathogenesis of HIV infection: What the virus spares is as important as what it destroys.
    https://www.nature.com/articles/nm1380
  3. Goldstein, L. A., Zhou, D. F. H., Picker, L. J., Minty, C. N., Bargatze, R. F., & Ding, J. F. (n.d.). A human lymphocyte homing receptor, the Hermes antigen, is related to cartilage proteoglycan core and link proteins.
    https://www.sciencedirect.com/science/article/abs/pii/0092867489906399

Assoc. Prof. Dr. Zhao Wang | Anti-HIV Drug | Best Researcher Award

Assoc. Prof. Dr. Zhao Wang | Anti-HIV Drug | Best Researcher Award

Shandong University | China.

Author Profile

Scopus

🎓EARLY ACADEMIC PURSUITS

Dr. Zhao Wang embarked on his academic journey with a strong foundation in pharmaceutical sciences, earning his Bachelor’s degree in Biochemistry from Shandong University, where he graduated with honors. He pursued his Ph.D. in Pharmacology at the same institution, focusing on antiviral mechanisms, solidifying his expertise in infectious diseases and drug development.

đŸ’ŒPROFESSIONAL ENDEAVORS

As an Associate Professor at Shandong University, Dr. Wang has built an esteemed career specializing in the development and delivery of antiviral drugs. His leadership in the university’s Pharmaceutical Innovation Laboratory has fostered groundbreaking discoveries in drug design, particularly targeting infectious diseases like HIV.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON ANTI-HIV DRUG

Dr. Wang’s most notable contributions lie in the field of Anti-HIV Drug Candidate Development. He has pioneered research on novel drug delivery systems, ensuring targeted, efficient, and safe delivery of antiviral agents. His work has significantly enhanced therapeutic efficacy and reduced side effects, addressing critical challenges in HIV treatment.
Key advancements include:

  • Developing nanoparticle-based delivery systems for enhanced antiviral drug bioavailability.
  • Designing small-molecule inhibitors targeting HIV replication mechanisms.
  • Exploring combination therapies to prevent resistance and improve patient outcomes.

🌍IMPACT AND INFLUENCE

Dr. Wang’s research has had a transformative impact on global health, particularly in low-resource settings where accessible and effective HIV treatments are paramount. His contributions have influenced international guidelines on antiviral drug administration and inspired collaborations with leading research institutions worldwide.

📚ACADEMIC CITATIONS

Dr. Wang’s work has garnered extensive recognition, with over 1,200 citations across peer-reviewed journals such as Antiviral Research and Journal of Medicinal Chemistry. His seminal papers on antiviral drug design are considered benchmarks in the field of HIV therapeutics.

🏆RESEARCH GRANTS AND FUNDING

Dr. Wang has secured substantial funding from prestigious organizations, including:

  • National Natural Science Foundation of China (NSFC)
  • World Health Organization (WHO)
  • Collaborative grants with pharmaceutical giants like Gilead Sciences

These funds have propelled his lab to the forefront of antiviral research.

🩠LEGACY AND FUTURE CONTRIBUTIONS

Dr. Wang’s commitment to advancing antiviral drug development extends beyond the lab. He actively mentors young researchers, fostering the next generation of scientists. His vision includes the integration of AI and machine learning to accelerate drug discovery processes, paving the way for even more effective treatments for HIV and other infectious diseases.

🌟A VISIONARY IN INFECTIOUS DISEASES

Dr. Zhao Wang is a trailblazer whose work exemplifies excellence in combating infectious diseases. His contributions to anti-HIV drug development have not only shaped the trajectory of antiviral therapy but also offered hope to millions affected by HIV worldwide.

📑NOTABLE PUBLICATIONS 

“Discovery of 2,4,6-trisubstituted pyrimidine derivatives as novel potent HIV-1 NNRTIs by exploiting the tolerant region II of the NNIBP”

Authors: Zhou, Z., Sun, Y., Qin, Y., … Kang, D., Liu, X.
Year: 2024
Journal: European Journal of Medicinal Chemistry

“Assessing the impact of long-term storage on the quality and integrity of biological specimens in a reproductive biobank”

Authors: Wang, Z., Zhang, C., Zhang, X., Bian, Y., Cao, Y.
Year: 2024
Journal: Bioengineering and Translational Medicine

“Discovery of Novel Amino Acids (Analogues)-Substituted Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Design, Synthesis, and Biological Evaluation”

Authors: Zhuo, Z., Wang, Z., Jing, L., … Liu, X., Kang, D.
Year: 2024
Journal: International Journal of Molecular Sciences

“Structure-based design, synthesis, and biological characterization of indolylarylsulfone derivatives as novel human immunodeficiency virus type 1 inhibitors with potent antiviral activities and favorable drug-like profiles”

Authors: Wang, Z., Wang, W., Gao, Z., … Zhan, P., Liu, X.
Year: 2024
Journal: Journal of Medical Virology

“Design and synthesis of Fsp3-enriched spirocyclic-substituted diarylpyrimidine derivatives as novel HIV-1 NNRTIs”

Authors: Sang, Z., Zhang, T., Wang, Z., … Zhan, P., Liu, X.
Year: 2024
Journal: Chemical Biology and Drug Design

Ms. Xiu Chen | HIV Treatment | Best Researcher Award

Ms. Xiu Chen | HIV Treatment | Best Researcher Award

Guangxi medical university, China.

Professional Profiles

Scopus Profile

🎓Education

Dr. Xiu Chen earned her Ph.D. in Epidemiology and Medical Statistics from Guangxi Medical University. Her academic training has equipped her with a solid foundation in statistical methods, epidemiological principles, and molecular research techniques, making her a valuable contributor to HIV/AIDS research.

 

đŸ’ŒExperience

With a focus on innovation, Dr. Chen has published eight high-impact articles in respected journals, including Emerging Microbes & Infections and Journal of Medical Virology. In addition, she has been granted a patent for her work on HIV/AIDS therapeutic strategies, showcasing her ability to translate research into practical applications.

 

🔍Research Interest

Dr. Chen’s primary research interest lies in identifying therapeutic targets for HIV/AIDS. Her work highlights the role of LncRNA LINC02453 in inhibiting HIV-1 replication, providing new insights into the virus’s resistance mechanisms. This focus underscores her dedication to developing innovative treatments to combat HIV/AIDS.

 

đŸ‘©â€đŸ«Technical Skills

Dr. Chen possesses expertise in identifying biomarkers, molecular characterization of HIV-1, and analyzing epidemiological data. Her technical skills enable her to uncover novel therapeutic targets and address critical challenges in combating HIV/AIDS.

 

📚Academic Citations 

Dr. Chen’s research has been featured in leading scientific journals, emphasizing her contributions to the field of HIV research. Her studies on molecular mechanisms and biomarkers have gained recognition in journals such as Frontiers in Immunology and BMC Public Health, reflecting her impact in advancing knowledge in HIV epidemiology and treatment.

📑Top Note Publications

Long Noncoding RNA LINC02453 Inhibits HIV-1 Replication by Binding With SEC13 to Regulate the Viral Productive Cycle

Authors: Chen, X., Chen, R., Wen, L., Liang, H., Jiang, J.
2024
Journal: Journal of Medical Virology

Application of ‘CDC-Public Security Bureau-NGO’ Joint Prevention and Control Mechanism Allied AIDS Prevention and Control in Guigang, Guangxi

Authors: Tao, X., Huang, Y., Zheng, P., Wei, F., Jiang, J.
2024
Journal: BMC Public Health

A Bibliometric Analysis of m6A Methylation in Viral Infection from 2000 to 2022

Authors: Tao, X., Wang, G., Wei, W., Ye, L., Jiang, J.
2024
Journal: Virology Journal

 Immunogenicity of an Inactivated COVID-19 Vaccine in People Living with HIV in Guangxi, China: A Prospective Cohort Study

Authors: Wu, Y., Wang, X., Huang, Y., Liang, H., Jiang, J.
Year: 2024
Journal: Viruses

Spectrum and Mortality of Opportunistic Infections Among HIV/AIDS Patients in Southwestern China

Authors: Meng, S., Tang, Q., Xie, Z., Zhou, B., Lin, J.
2023
Journal: European Journal of Clinical Microbiology and Infectious Diseases